Lepton Pharmaceuticals

Lepton Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing highly selective inhibitors of Matrix Metalloproteinases (MMPs). The company's proprietary platform addresses the historical challenge of MMP inhibitor toxicity by specifically targeting MMP-2 and MMP-9 while sparing other family members. Their lead candidate, LEP-103, is a small molecule designed to penetrate the blood-brain barrier for the treatment of neuroinflammatory conditions like multiple sclerosis. Additionally, Lepton is exploring the potential of its selective inhibitors in oncology, particularly for aggressive cancers like glioblastoma. By leveraging structural insights from the Weizmann Institute of Science, the company aims to unlock the therapeutic potential of MMPs across multiple high-need indications.